Cerecin key facts
- Developer of therapeutics technology designed to treat memory impairment and other neurodegenerative diseases.
- It has raised $316.7M across 4 recorded rounds; the latest was Debt ($3.7M) in Jun 2024.
- Notable investors include Partners Investment, AFW Partners, Shinhan Securities, IBK Capital, Medici Investment — 12 tracked in total.
- Cerecin has filed 4 Form Ds with the SEC since 2021, most recently Jun 2024 ($3.7M sold to 10 investors).
- Status: Privately Held (backing).
Who backs Cerecin
12+- ·The complete investor list: 12 names
- ·Watch Cerecin: the Monday email on marks, rounds and moves
Cerecin funding rounds
4 roundsHow much has Cerecin raised?
Cerecin has raised $317 million in total; 4 of its rounds are on record, from 2021 on. The largest on record was a $7.2 million early-stage round in Aug 2022; the most recent was a $3.7 million debt round in Jun 2024.
Cerecin has filed 4 Form Ds with the SEC since 2021, most recently in Jun 2024 ($3.7 million sold to 10 investors).
Cerecin investors
12 investors are on record for Cerecin, including Partners Investment, AFW Partners, Shinhan Securities and IBK Capital. The debt round in Jun 2024 drew 10 investors.
About Cerecin
Developer of therapeutics technology designed to treat memory impairment and other neurodegenerative diseases. The company offers lipid science to explore the potential therapeutic benefits of medium-chain triglycerides which are designed to induce ketosis and improve mitochondrial metabolism and develops novel evidence-based alternatives that help people, pharmaceuticals, medical foods, diagnostics, medical devices, and e-health products, enabling clinicians to have access to brain health-focused products and therapies to treat diseases of the brain.
- Sector
- Healthcare
- HQ
- Denver, CO, United States
- Founded
- 2000
- Employees
- 38
- Website
- cerecin.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Cerecin doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.